Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.46 |
| ▸ | TP53 | P04637 | 7/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PMM2 | O15305 | 1/20 | 0.34 |
| ▸ | G6PD | P11413 | 1/20 | 0.34 |
| ▸ | MPI | P34949 | 1/20 | 0.34 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423281 | 0.80 | CYP2A6 (0.64) | MAPTTP53CA2THRBUSP2 | |
| SCHEMBL7541080 | 0.78 | MAPT (0.45) | MAPTTP53CA2THRBUSP2 | |
| SCHEMBL422138 | 0.77 | CYP2A6 (0.50) | MAPTTP53CA2THRBUSP2 | |
| SCHEMBL8147097 | 0.77 | CA2 (0.47) | MAPTTP53CA2THRBUSP2 | |
| SCHEMBL19099909 | 0.77 | MAPT (0.44) | MAPTTP53CA2THRBUSP2 | |
| SCHEMBL17140096 | 0.77 | MAPT (0.44) | MAPTTP53CA2THRBUSP2 | |
| Hydrochloric Acid SCHEMBL31167195 | 0.75 | CA2 (0.46) | MAPTTP53CA2THRBUSP2 | |
| SCHEMBL23012016 | 0.74 | CYP2A6 (0.56) | MAPTTP53CA2CYP2A6IDO1 | |
| SCHEMBL18935978 | 0.74 | CYP2A6 (0.34) | MAPTTP53CA2CYP2A6LMNA | |
| SCHEMBL7917778 | 0.74 | CYP2A6 (0.62) | MAPTTP53CA2CYP2A6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | SMITHKLINE BEECHAM P.L.C. | 2004-11-11 | — | — | US | disclosed |
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-23 | — | — | US | disclosed |
| EP-1244616-A1 | (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | SmithKline Beecham plc (GB) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047874-A1 | (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | CD40, CD22, CD2 | MAPT 4878/4885TP53 1628/4885CA2 673/4885 |
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | CD40, TNFRSF1A, CD2 | MAPT 4878/4885TP53 1939/4885CA2 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.